A promising new vaccine for SARS-CoV-2 and influenza

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, along with the continuous transmission of influenza viruses and other coronaviruses, remains a serious global threat to public health. Due to the high mortality and morbidity associated with the coronavirus disease 2019 (COVID-19), several vaccines were developed at a record speed to reduce the transmission of SARS-CoV-2. Despite this achievement, the emergence of neutralizing antibody-resistant SARS-CoV-2 variants, combined with the threat of SARS-CoV-2 becoming endemic, suggest that vaccine development must continue to evolve. Thus, many researchers around the world have expressed interest in producing a vaccine that could simultaneously target SARS-CoV-2, as well as other types of CoVs. Background Prior to the emergence of SARS-CoV-2, influenza A viruses (IAVs) were the most common cause of respiratory diseases posed a huge danger to world health and the economy. Influenza vaccines must be administered once a year, with efficacy varying each year and often being...